ArticleExperimental hematology & oncology2012
Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011.
Article in Experimental hematology & oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.Journal of hematology & oncology · 2013Trial
- Allogeneic Stem Cell Transplant in Hematological Disorders: A Decade of Experience.International journal of hematology-oncology and stem cell research · 2024Article
- Outcome of donor and recipient sex match versus mismatch in stem cell transplant procedure.International journal of hematologic oncology · 2019Article
- Pulmonary hypertension associated with thalassemia syndromes.Annals of the New York Academy of Sciences · 2016Review
- SEA antagonizes the imatinib-meditated inhibitory effects on T cell activation via the TCR signaling pathway.BioMed research international · 2014Article
- Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation.Journal of hematology & oncology · 2013Review
- The role of peptide and DNA vaccines in myeloid leukemia immunotherapy.Cancer cell international · 2013Article
- Herpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present our initial experience of allogeneic stem cell transplant procedure performed between April 2004 and August 2011 for various haematological disorders. All patients with non-malignant and malignant haematological disorders with HLA matched donors were selected after pre-transplant workup. Ninety seven patients underwent the procedure. Most common indications for transplant were aplastic anaemia in n = 34 (35%), followed by β-Thalassemia major in n = 21 (21.6%) and chronic myeloid leukemia in n = 11 patients (11.3%). Primary graft failure present was present in 2.06%. Incidence of graft versus host disease (GvHD) in our patients was 34%. After median follow-up of five years the overall survival was 71.3% with a mean survival time of 51.2 ± 3.3 months.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.